Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, August 15, 2013 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it has obtained the marketing approval of Irribow® OD 1)...
Tokyo and San Francisco -- July 30, 2013 -- Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of...
NORTHBROOK, Ill. July 19, 2013 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug...
Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “Company”) today announced that it decided the contents of the stock acquisition rights...
Tokyo: June 28, 2013 – Toa Eiyo Ltd. (Tokyo; Unlisted; “Toa Eiyo”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that Toa Eiyo has obtained the marketing approval...
BOTHELL, Wash., & SANTA MONICA, Calif., June 27, 2013 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced...
San Francisco, CA and Tokyo – June 26, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced enrollment of the first patient in a global Phase 2 clinical...
SAN DIEGO & TOKYO—June 25, 2013—Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced the initiation of a multinational Phase 3 registration trial of ASP0113...
Follow us
